154 related articles for article (PubMed ID: 18179962)
21. Approach to new therapeutics: investigation by the use of MDS-derived cell lines.
Tsujioka T; Matsuoka A; Tohyama Y; Tohyama K
Curr Pharm Des; 2012; 18(22):3204-14. PubMed ID: 22571700
[TBL] [Abstract][Full Text] [Related]
22. Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society.
Meers S; Breems D; Bries G; Delforge M; Graux C; Ravoet C; Selleslag D; Noens L;
Acta Clin Belg; 2013; 68(4):253-62. PubMed ID: 24455794
[TBL] [Abstract][Full Text] [Related]
23. Myelodysplastic syndromes.
Scott BL; Deeg HJ
Annu Rev Med; 2010; 61():345-58. PubMed ID: 20059342
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Prebet T; Charbonnier A; Gelsi-Boyer V; Mozziconacci MJ; Blaise D; Vey N
Leuk Lymphoma; 2013 Jul; 54(7):1538-40. PubMed ID: 23110702
[No Abstract] [Full Text] [Related]
25. [New tools and treatments in myelodysplastic syndromes].
Cluzeau T; Fenaux P
Rev Med Interne; 2013 Mar; 34(3):159-67. PubMed ID: 22766158
[TBL] [Abstract][Full Text] [Related]
26. More is better: combination therapies for myelodysplastic syndromes.
Ornstein MC; Mukherjee S; Sekeres MA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
[TBL] [Abstract][Full Text] [Related]
27. Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure.
Carraway HE
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):470-477. PubMed ID: 27913518
[TBL] [Abstract][Full Text] [Related]
28. MDS: unraveling the mystery.
Rizzieri DA
Blood; 2012 Dec; 120(25):4906-8. PubMed ID: 23243154
[TBL] [Abstract][Full Text] [Related]
29. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
30. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
31. Novel biospecific agents for the treatment of myelodysplastic syndromes.
Gotlib J; Greenberg PL
J Natl Compr Canc Netw; 2003 Oct; 1(4):473-80. PubMed ID: 19774739
[TBL] [Abstract][Full Text] [Related]
32. MDS: navigating the complex course.
Fortenbaugh C
ONS News; 2006; 21(8 Suppl):17-8. PubMed ID: 16925134
[No Abstract] [Full Text] [Related]
33. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Steensma DP
Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
[TBL] [Abstract][Full Text] [Related]
34. [Current treatment options for myelodysplastic syndromes].
Nolte F; Hofmann WK
Dtsch Med Wochenschr; 2010 Sep; 135(38):1863-9. PubMed ID: 20842606
[No Abstract] [Full Text] [Related]
35. [Management of myelodysplastic syndromes].
Duchmann M; Fenaux P; Cluzeau T
Bull Cancer; 2015 Nov; 102(11):946-57. PubMed ID: 26410692
[TBL] [Abstract][Full Text] [Related]
36. Risk-based management of myelodysplastic syndrome.
Steensma DP; Tefferi A
Oncology (Williston Park); 2007 Jan; 21(1):43-54; discussion 57-8, 62. PubMed ID: 17313156
[TBL] [Abstract][Full Text] [Related]
37. [Myelodysplastic syndrome].
Mitani K
Nihon Rinsho; 2008 Mar; 66(3):513-9. PubMed ID: 18330027
[TBL] [Abstract][Full Text] [Related]
38. The role of decitabine in the treatment of myelodysplastic syndromes.
Atallah E; Kantarjian H; Garcia-Manero G
Expert Opin Pharmacother; 2007 Jan; 8(1):65-73. PubMed ID: 17163808
[TBL] [Abstract][Full Text] [Related]
39. "Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
Thakral B; Wang SA
Blood; 2017 Sep; 130(13):1600. PubMed ID: 28963106
[No Abstract] [Full Text] [Related]
40. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
